Literature DB >> 32970228

Apical surgery in cancer patients receiving high-dose antiresorptive medication-a retrospective clinical study with a mean follow-up of 13 months.

Sanne Werner Moeller Andersen1, Simon Storgaard Jensen2,3, Morten Schiodt2,4.   

Abstract

PURPOSE: The aim of the study is to evaluate the results of apical surgery (AS) in patients receiving high-dose antiresorptive medication (HDAR).
METHODS: Retrospective descriptive quality control study conducted in an Oral and Maxillofacial Department at a University Hospital. Fourteen patients on HDAR met the inclusion criteria. Only descriptive statistics were applied.
RESULTS: Fourteen patients had operation on seventeen teeth. Mean HDAR treatment period before apical surgery: 25 months (SD, ± 24.27; range, 1-78 months). Drug holiday during surgery and initial healing: mean, 8 months (SD, ± 5.96; range, 0.4-22 months). Sixteen out of seventeen teeth healed clinically and showed complete or ongoing radiographic healing. All patients except one became free of symptoms. Mean follow-up: 13 months (SD, ± 9.05; range, 2-31 months). Radiographic healing according to Molven and Rud: 7, complete; 6, uncertain; 1, unsatisfactory. Three patients died during follow-up and were considered drop-outs.
CONCLUSIONS: The present case series suggest that apical surgery is a valid treatment option for apical periodontitis in patients on HDAR, where orthograde endodontic retreatment is not possible. None of the patients developed medication-related osteonecrosis of the jaw. Further studies in larger study groups and with longer follow-up periods are needed. The regional scientific ethical committee provided a document exemption, registration date 20 November 2013, and the local data protection agency approved handling of the recorded data (No. 2012-41-0045), registration date 11 January 2012.

Entities:  

Keywords:  Antiresorptive medication; Apical surgery; Bisphosphonate; Cancer; Denosumab

Mesh:

Substances:

Year:  2020        PMID: 32970228     DOI: 10.1007/s10006-020-00909-9

Source DB:  PubMed          Journal:  Oral Maxillofac Surg        ISSN: 1865-1550


  23 in total

Review 1.  Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment.

Authors:  Ourania Nicolatou-Galitis; Morten Schiødt; Rui Amaral Mendes; Carla Ripamonti; Sally Hope; Lawrence Drudge-Coates; Daniela Niepel; Tim Van den Wyngaert
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2018-10-09

Review 2.  Outcomes of surgical endodontic treatment performed by a modern technique: an updated meta-analysis of the literature.

Authors:  Igor Tsesis; Eyal Rosen; Silvio Taschieri; Yoel Telishevsky Strauss; Valentina Ceresoli; Massimo Del Fabbro
Journal:  J Endod       Date:  2013-01-23       Impact factor: 4.171

3.  Bisphosphonate-associated osteonecrosis of jaw reoccurrence after methotrexate therapy: a case report.

Authors:  Fahd Alsalleeh; Jeffery Keippel; Lyde Adams; Bruce Bavitz
Journal:  J Endod       Date:  2014-03-06       Impact factor: 4.171

4.  Assessing the association between bisphosphonate exposure and delayed mucosal healing after tooth extraction.

Authors:  Cesar A Migliorati; Deborah Saunders; Michael S Conlon; Hanne Kleven Ingstad; Paul Vaagen; Mitzi J Palazzolo; Bente B Herlofson
Journal:  J Am Dent Assoc       Date:  2013-04       Impact factor: 3.634

5.  Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.

Authors:  Robert E Marx; Yoh Sawatari; Michel Fortin; Vishtasb Broumand
Journal:  J Oral Maxillofac Surg       Date:  2005-11       Impact factor: 1.895

6.  Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: A trigger for BRONJ development?

Authors:  Sven Otto; Matthias Tröltzsch; Vesna Jambrovic; Sappasith Panya; Florian Probst; Oliver Ristow; Michael Ehrenfeld; Christoph Pautke
Journal:  J Craniomaxillofac Surg       Date:  2015-04-10       Impact factor: 2.078

7.  Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.

Authors:  Konstantinos Vahtsevanos; Athanassios Kyrgidis; Evgenia Verrou; Eirini Katodritou; Stefanos Triaridis; Charalampos G Andreadis; Ioannis Boukovinas; Georgios E Koloutsos; Zisis Teleioudis; Kyriaki Kitikidou; Panagiotis Paraskevopoulos; Konstantinos Zervas; Konstantinos Antoniades
Journal:  J Clin Oncol       Date:  2009-10-05       Impact factor: 44.544

Review 8.  Bisphosphonates and their clinical implications in endodontic therapy.

Authors:  A-T Moinzadeh; H Shemesh; N A M Neirynck; C Aubert; P R Wesselink
Journal:  Int Endod J       Date:  2012-11-09       Impact factor: 5.264

9.  Principles of oral surgery for prevention of bisphosphonate-related osteonecrosis of the jaw.

Authors:  Marcus J Heufelder; Joerg Hendricks; Torsten Remmerbach; Bernhard Frerich; Alexander Hemprich; Frank Wilde
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2012-11-20

10.  A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer.

Authors:  Morten Schiodt; Saroj Vadhan-Raj; Mark S Chambers; Ourania Nicolatou-Galitis; Constantinus Politis; Ruxandra Coropciuc; Stefano Fedele; Danielle Jandial; Jeffrey Zhang; Haijun Ma; Deborah P Saunders
Journal:  Support Care Cancer       Date:  2017-12-23       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.